Funding for this research was provided by:
National Natural Science Foundation of China (81570835)
Beijing Municipal of Health Reform and Development Project (2019-4)
Medizinische Fakultät Mannheim der Universität Heidelberg
Article History
Received: 27 September 2021
Accepted: 15 December 2021
First Online: 24 December 2021
Declarations
:
: The Medical Ethics Committee of Beijing Tongren Hospital approved the study protocol according to the declaration of Helsinki and all study participants gave their written informed consent.
: All study participants gave their written informed consent.
: Jost B. Jonas and Rahul A. Jonas: European patent application 16 720 043.5 and US patent application US 2019 0085065 A1: „Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia). Patent application: Agents for the use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases.